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ABSTRACT:
The CYP3A subfamily of cytochromes P450 metabolize many mcdi-
cations and environmental contaminants. CYP3A4 and, in 25% of
patients, CYP3A5 seem to be the major CYP3A genes expressed in
adult liver. Hepatic levels of CYP3A4 can be estimated by the
erythromycin breath test and vary at least 10-fold among patients.
CYP3A4 has also been shown to be present in small bowel where it
is responsible for significant “first-pass” metabolism of orally ad-
ministered substrates. However, it is not known whether there is
significant interindividual variability in the intestinal expression of
CYP3A4, or whether the liver and intestinal catalytic activities of
CYP3A4 conelate within an individual. It is also not known whether
CYP3A5 is expressed in the small intestine. To address these ques-
tions, we administered the erythromycin breath test to 20 patients
and obtained biopsies from their small bowel. There was a 6-fold
variation in CYP3A catalytic activfty (midazolam hydroxylation), an
11-fold variation in CYP3A4 protein content, and an 8-fold variation
in CYP3A4 mRNA content in intestinal biopsies. There was an cx-
cellent correlation between intestinal CYP3A4 protein level and cat-
alytic activity (r = 0.86; p = 0.0001); however, neither parameter
significantly correlated with hepatic CYP3A4 activity as measured
by the erythromycin breath test resuft (r = 0.27; p = 0.24 and r =
0.33; p = 0.15, respectively). We also found that CYP3A5 protein
was readily detectable in biopsies from 14 (70%) of the patients,
indicating that CYP3A5 is commonly expressed in human small
intestine. We conclude that there is marked interpatient heteroge-
neity in intestinal expression of CYP3A4 and CYP3A5, which is likely
to contribute to the heterogeneous kinetics of orally administered
CYP3A substrates. We also conclude that hepatic and intestinal
CYP3A4 activities do not correlate well within individuals. Therefore,
assays of liver CYP3A4 catalytic activity, such as the erythromycin
breath test, do not provide an accurate means of assessing intestinal
CYP3A catalytic activity.
Members of the cytochrome P450 subfamily termed 3’
have been shown to metabolize a growing list ofcommonly used
medications, including erythromycin, cyciosporin A, 17 ct-ethi-
nyl estradiol, midazolam, lidocaine, lovastatin, and some cal-
cium channel blockers (reviewed in ref. 2). CYP3A enzymes
have also been implicated in the metabolism of many potentially
toxic environmental chemicals, such as mycotoxins (3), pyrroli-
zidine alkaloids (4), and aryl hydrocarbons (5).
Four different CYP3A cDNAs have been cloned from human
liver libraries and have been termed CYP3A3, CYP3A4,
CYP3A5, and CYP3A 7 ( 1). CYP3A4 seems to be the major
CYP3A enzyme present in adult liver (6) and has been detected
in essentially all adult livers examined to date. The hepatic
concentration of CYP3A4 protein and catalytic activity have
been found to vary at least 10-fold among patients (2). The other
This study was supported by the National Institutes of Health (Grant
P01 ES04238 to P.6W.), Roche Laboratories (to K.L.K. and K.E.T.), and the
General Clinical Research Center (Grant MOl RR00042).
1 The cytochromes P450 are a gene superfamily that has been divided into
families that share >40% amino acid sequence identity and subfamilies that share
>70% amino acid Identity. In this study, we refer to specific P450s according to
the recently recommended CYP’ nomendature (1). P450s within the CYP3A
subfamily have been termed #{176}P450111A’in our former publications.
major adult liver CYP3A enzyme seems to be CYP3A5; however,
this enzyme is present in only 25% ofadult livers (7, 8). Although
CYP3A4 and CYP3A5 have over 85% amino acid identity, their
catalytic properties seem to be different. For example, CYP3A4
N-demethylates erythromycin roughly 10-fold faster than does
CYP3A5 (9). In addition, both CYP3A4 and CYP3A5 readily
metabolize cyclosporin A, but the pattern of metabolites gener-
ated by each enzyme differs (7).
The activity of liver CYP3A4 can be estimated from the rate
at which a patient exhales ‘4CO2 after receiving a trace intrave-
nous dose of [‘4C-N-methyl]erythromycin (10, 1 1). This test is
based on the observation that CYP3A4 exclusively catalyzes the
N-demethylation of erythromycin in liver microsomes ( 10) and
that the carbon atom in the resulting formaldehyde should largely
appear in the breath as CO2 (12). Several lines of evidence
strongly support the idea that this ERMBT2 specifically measures
CYP3A4. First, ERMBT results significantly rise or fall in pa-
tients after they are given either inducers or inhibitors, respec-
tively, ofCYP3A4 (10). In addition, the ERMBT results predict
the kinetics of the orally administered specific substrates for
CYP3A4, cyclosporin A (13, 14) and OG37-325 (15). Finally,
in patients with severe liver disease who underwent liver biopsy
after receiving the ERMBT, the results of the breath test corre-
lated significantly with the liver microsomal concentration of
2 Abbreviations used are: ERMBT, erythromycin breath test; PCR, polymerase
chain reaction; SDS, sodium dodecyl sulfate; 1 ‘-OH, 1 ‘-hydroxy midazolam; 4-OH,
4-hydroxy midazolam.
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CYP3A immunoreactive protein (1 1). In this same study, the
ERMBT results did not correlate at all with the microsomal
concentration of four other major liver P450s.
It has recently been reported that CYP3A4 is also present in
the epitheiial cells (enterocytes) lining the small bowel ( 16) and
that intestinal CYP3A4 seems to account for significant “first-
pass” metabolism of orally administered cyciosporin A (17). It is
possible that variations in intestinal expression of CYP3A en-
zymes may account for a significant portion of the variability in
oral cyclosporin A pharmacokinetics (1 7). However, it is not
known whether there is heterogeneity in the expression of intes-
tinal CYP3A4 in patient populations or whether CYP3A5 is
expressed in the intestine.
It is also not known whether the ERMBT is able to predict
intestinal activity of CYP3A enzymes. For several reasons, it
seems likely that the ERMBT primarily measures hepatic
CYP3A4 activity. First, the intravenous administration of the
test dose of erythromycin should in essence “bypass” the intes-
tinal CYP3A4. Second, although the kidney expresses CYP3A
enzymes, the liver contains a much larger mass of CYP3A
enzymes than the kidney [the only other nongastrointestinal
tract organ conclusively shown to express CYP3A enzymes
(18)1. Finally, the liver specificity ofthe ERMBT is supported by
the fact that the test results are dramatically lower than normal
in patients with severe liver disease (1 1) and during the anhepatic
phase of liver transplant surgery (19). However, if the CYP3A4
gene were coordinately regulated in liver and intestine, the liver
CYP3A4 activity measured by the ERMBT result should also
correlate with intestinal CYP3A4 activity.
The primary aims of this study were, therefore, to determine
whether there is significant interpatient heterogeneity in intes-
tinal expression of CYP3A enzymes and, if so, whether the
ERMBT predicts CYP3A catalytic activity in the intestine. To
address these questions, we administered the ERMBT to 20
patients and analyzed biopsies from their small bowel for
CYP3A4 and CYP3A5 proteins, CYP3A4 mRNA, and CYP3A
catalytic activity.
Materials and Methods
Population. Subjects were recruited from among outpatients who had
been previously scheduled by their attending physicians to undergo upper
intestinal endoscopy for various clinical indications. Written informed
consent was obtained from 20 subjects who agreed to participate in the
study. Patients under the age of 18 or women of childbearing potential
were excluded to minimize the theoretical risks associated with the use
of carbon-14. Patients were also excluded if they were taking any mcdi-
cations known to induce or inhibit CYP3A activity, including glucocor-
ticoids, macrolide antibiotics, antiseizure medications, or imidazole an-
timycotic medications (20). Finally, patients were excluded if they had
any known small bowel disease or had any contraindications to having
small bowel biopsies taken (i.e. abnormalities in blood clotting). This
study was approved by the Institutional Review Board at the University
of Michigan.
ERMBT. Patients were given the ERMBT, as previously described,
before receiving any medications or sedation for the endoscopy. Briefly,
patients were given an intravenous dose of 0.074 mmol (3 iCi) of [‘4C-
N-methyljerythromycin. At timed intervals after the injection, patients
were asked to exhale through a tube creating bubbles in a hyamine
solution formulated to trap exactly 2 mmol ofcarbon dioxide. The vials
were capped and the specific activity of ‘4C determined by scintillation
counting. Breath test results were expressed as the percentage of admin-
istered ‘4C that was exhaled during the first hour after the injection of
erythromycin (10). Because CYP3A5 does not readily metabolize eryth-
romycin (9), the results of the ERMBT should not be influenced by the
expression ofCYP3A5 in liver.
Protein and RNA Isolation. Ten small bowel biopsies distal to the
duodenal bulb were obtained from each patient at the time of endoscopy.
Five of the biopsies were immediately placed in 400 .il of denaturing
solution (4 M guanidine isothiocyanate, 0.5% N-lauroylsarcosine, 25
mM sodium citrate, and 0.7% 2-mercaptoethanol; pH 7.0) and frozen at
-70#{176}C.At a later time, the samples were quickly thawed and the RNA
extracted by the method ofChomczynski and Sacchi (21). The other five
samples were placed in solution D (0.05 M Tris-HC1, 20% glycerol, and
2 mM EDTA) (22). An 59 fraction was then prepared as previously
described (23, 24).
RNA Analysis. Thirty g oftotal RNA from each patient was subjected
to electrophoresis on a formaldehyde agarose gel containing ethidium
bromide. After visualizing the ribosomal bands with UV light, the RNA
was transferred to nylon membranes by positive pressure using a Posi-
blotter (Stratagene, La Jolla, CA). The cDNA probes used were synthe-
sized as follows. Thirty base pair synthetic oligonucleotide primers spe-
cific for CYP3A4 (16) were used in the PCR. The 382 base pair DNA
fragment amplified from cDNA made from human intestinal RNA was
then cloned into pBluescript KS(Stratagene)using a modified TA cloning
procedure (25) and sequenced at least 3 times to confirm its identity with
the published sequence of CYP3A4. The same PCR cloning technique
was used to generate and confirm the identity of a human villin cDNA
probe. The cDNA probes were labeled by random priming with 32P
(Amersham Corporation, Arlington Heights, IL) to a specific activity of
-1 x l0 cpm/g. Hybridizations with cDNA probes were conducted at
65#{176}Cfor 18 hr as previously described (26). The blots were washed twice
at 65#{176}Cand placed with X-ray film for 3 and 12 hr for detection of
CYP3A4 and villin mRNAs, respectively. The relative hybridization
intensities with the CYP3A4 and villin cDNAs were quantitated by
computer-assisted densitometry and expressed as arbitrary optical density
units.
Protein Analysis. Protein concentrations were determined by a mod-
ification of the Lowry assay (27). Fifty g of the 59 fraction were mixed
in sample buffer containing SDS and 2-mercaptoethanol and heated at
100#{176}Cfor 5 mm. The samples were then subjected to electrophoresis in
10% polyacrylamide/0. 1% SDS gels. After 2 hr of electrophoresis, serial
dilutions ofeither purified CYP3A4 protein or intestinal S9 protein from
a reference patient (to serve as standards for villin determinations) were
second-loaded on the gel (28), and the electrophoresis was continued for
an additional 2 hr. The samples were then transferred to nitrocellulose
by the method of Towbin et a!. (29). The blots were blocked for 1 hr in
Tris-buffered saline containing 0.3% Tween 20 (Sigma Chemical Com-
pany, St. Louis, MO) and 5% nonfat dry milk (Carnation). The filters
were then incubated with either a rabbit polyclonal antibody specific for
CYP3A5 (9), a mouse monoclonal antibody raised against chick villin
that has been shown to cross-react with human villin [(30) a generous
gift from A. Brian West, Yale Universityl, or a mouse monoclonal
antibody specific for human CYP3A proteins (9, 31, 32). The latter
antibody reacts with all CYP3A proteins. However, because CYP3A4 is
the major CYP3A protein expressed in the intestine (16), the amount of
antibody bound on the immunoblots should primarily reflect CYP3A4
protein levels. The protein identified by this antibody is, therefore,
referred to as CYP3A4 in these studies.
After extensive washing with Tris-buffered saline containing 0.3%
Tween 20 and 0.25% nonfat dry milk, the blots were incubated with a
secondary antibody (either rabbit antimouse or goat antirabbit antibody)
conjugated with peroxidase. Further washings were done with Tris-
buffered saline containing 0.3% Tween 20 and 0.25% nonfat dry milk,
with a final washing ofTris-buffered saline containing only 0.3% Tween
20. The filters were then developed with a chemiluminescence kit (Amer-
sham) and exposed to Hyperfilm ECL (Amersham) for 1 sec to 15 mm,
depending on the intensity ofthe bands.
CYP3A Catalytic Activity Analysis. We found that measurements of
erythromycin or cyclosporin A metabolism that were previously used to
quantitate CYP3A catalytic activity (16, 33) were not sufficiently sensi-
tive for the purposes of this study (data not shown). This reflects the fact
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that these substrates are not rapidly metabolized by CYP3A enzymes
and that the enzymes are present in relatively low concentrations in
patients who have not been receiving inducers of CYP3A. We therefore
analyzed the ability of the biopsy 59 protein fractions to metabolize
midazolam to its 1 ‘- and 4-OH metabolites.
S9 supernatant from each intestinal biopsy sample was thawed and
suspended in cold potassium phosphate buffer (0. 1 M, pH 7.4) to reach
a final protein concentration of 100 tg in a 1 ml volume. Midazolam
was added to a final concentration of 4 M, and the resulting mixtures
were gently agitated within a Dubnoff metabolic shaking incubator at
37C for 3 mm. The reaction was started with the addition of NADPH
( 1 mM final concentration) and terminated after 5 mm by the addition
of 1 ml of 100 mM Na2CO3 (final pH 1 1). The samples were spiked with
10 ng of D2-l ‘-OH midazolam and extracted twice with 2 volumes of
ethyl acetate. After extraction, solvent was removed under nitrogen and
the concentrated extracts were dissolved in 80 l of derivatizing reagent
[20% N-(tert butyldimethylsilyl)-N-methyltrifluoroacetamide in aceto-
nitric]. The samples were transferred to autoinjector vials and sealed
before being heated to 80C for 2 hr. Quantification of 1 ‘-OH midazolam
and 4-OH midazolam was performed by GC-negative chemical ioniza-
tion-mass spectrometry operated in the selective ion monitoring mode.
The mass spectrometer was a VG model Trio 1000 interfaced to a
Hewlett-Packard 5890A gas chromatograph equipped with a Hewlett-
Packard 7376A autoinjector and a DB-l7 fused capillary column (30 m
x 0.32 mm i.d., 0.25-tm film thickness: J & W Scientific, Ventura, CA).
Helium carrier gas was used at a head pressure of 7 psi, and injections
were made in the splitless mode. The injector and transfer line temper-
atures were held at 250CC and 290C, respectively. The injection volume
was 2 i. The oven temperature was held at 1 10#{176}Cfor 1 mm, increased
at 25C/min to 290C, held for 5 mm, increased at 40C/min to 300C
and then held for a final 3 mm. Under these conditions, the derivatives
of 4-OH midazolam and 1 ‘-OH midazolam eluted with retention times
of 9.4 and 10.0 mm, respectively. The base peak fragment ions [M-
tBu(CH3)2SiOHj at ml: 323 were monitored for both metabolites. The
D2-l ‘-OH midazolam internal standard also eluted at a retention time
of 10.0 mm and was monitored at m/z 327, the base peak fragment ion
of the 37C1 isotopic species. Methane was used as the reagent gas and the
source temperature held at 200#{176}C.Concentrations of 1 ‘-OH midazolam
and 4-OH midazolam were quantified by comparing peak area ratios
from unknown samples to their respective standard curves (area ratio vs.
concentration) prepared from the addition of known amounts of 1 ‘-OH
midazolam, 4-OH midazolam, and D2-l ‘-OH midazolam to human liver
microsomes suspended in phosphate buffer.
Results
ERMBT Results. Twenty patients (1 1 men and 9 women)
were enrolled in the study. A list oftheir age, sex, and medication
profiles is shown in table 1 . Each patient was given the ERMBT
before receiving any medications for the endoscopy. Intestinal
biopsies were obtained during the endoscopic procedure from
the second portion of the duodenum and processed for either
protein or RNA analysis as described in Materials and Methods.
There was >7-fold interpatient heterogeneity in the ERMBT
results (mean of 3.3 ± 1.3 SD % administered ‘4C exhaled over
1 hr; see table 2). Women had a higher mean ERMBT value
than did men, but this was not significant (3.7% vs. 3.0%,
respectively, p = 0.25).
Protein and RNA Correction for Enterocyte Content of Biop-
sies. Because CYP3A enzymes are expressed exclusively in ma-
ture enterocytes in the intestine (16, 32), differences in the
percentage of enterocyte content by weight in individual intes-
tinal biopsies might alter our results. For example, a deep mu-
cosal biopsy would contain a relatively low proportion of enter-
ocytes, whereas a more superficial biopsy would have a relatively
high proportion ofenterocytes. A shallow biopsy should therefore
have a higher concentration of CYP3A protein and mRNA/mg
Pa tieni characteristics and medication profiles
Patient Age Sex Medications
1 65 F Furosemide, levothyroxine, spironolactone
2 54 F Cisapride, furosemide, insulin, metoclopramide,
omeprazole, ranitidine
3 45 F Atenolol, estrogen, famotidine, hydrocrotisone
cream, tolmetin
4 34 M Amitriptyline, hydroxychloroquine, ibuprofen,
oxycodone/acetaminophen, ranitidine
S 6 1 M Captopril, insulin, isosorbide dinitrate, thiethyl-
perazine maleate
6 53 F Aiprazolam, omeprazole
7 54 M Aspirin
8 66 F Aspirin, diphenoxylate/atropine, estradiol patch
9 57 M Aspirin, famotidine, ibuprofen, nifedipine
10 74 F Diltiazem
1 1 40 M Metronidazole
12 62 M Aspirin, piroxicam, ranitidine, trazodone, terfen-
adine
13 51 M Aspirin,vitaminC
14 34 M Ranitidine
IS 60 F Levothyroxine, lorazepam, ranitidine
16 44 F Dicyclomine, hydroxyzine pamoate, imipra-
mine, oxycodone/acetaminophen, pancreatin,
propranolol, omeprazole, triazolam, trime-
thobenzamide
17 76 F Calcium, estrogen, ferrous sulfate, hydrocodone,
misoprostol, sulfasalazine, sulindac, triamter-
ene/hydrochiorothiazide
18 32 M Ranitidine
19 26 M Doxepin, ranitidine
20 49 M Atenolol, omeprazole
of tissue than a deep biopsy obtained from the same individual.
Another potential source of variability in the CYP3A content of
biopsies is proteolysis due to digestive enzymes. It is logical to
assume that enterocytes, due to their location adjacent to the gut
lumen, might be especially susceptible to proteolysis during tissue
procurement and processing. To correct for these factors, it
seemed essential to identify an enterocyte specific mRNA and
protein that would have little intrapatient or interpatient varia-
bility to serve as an internal standard for our studies.
Villin, a constitutively expressed protein that is enterocyte-
specific (30), seemed to be an ideal candidate for our purposes.
To verify the usefulness ofvillin as a standard, we endoscopically
obtained biopsies from the second portion of the duodenum in
two patients. In one patient, six biopsies were obtained within
mm of each other, and, in the second patient, six biopsies were
obtained at least 1 cm apart. Each biopsy was homogenized
separately and run as an individual sample on an immunoblot.
The blot was developed first with a monoclonal antibody specific
for CYP3A and then redeveloped with a monoclonal antibody
specific for human villin. There was significant interbiopsy var-
iation in the content of CYP3A immunoreactive protein, both
among biopsies obtained at a single site (fig. lA 1, mean 304.9 ±
43.2 SD optical density units/mg protein) and among biopsies
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TABLE 2
Valuesfor ERMBT and enterocyte CYP3A4 protein, CYP3A4 mRNA,
and 1 ‘-OH midazolam rate
CYP3A4 protein, CYP3A4 mRNA, and 1 ‘-OH midazolam formation
rates are expressed relative to villin expression to compensate for inter-
biopsy variations in enterocyte content and protein degradation.
. . CYP3A4 1‘-OH
Patient ERMBT CYP3A4 Protein mRNA Midazolam
% 14( [mo//mg protein/ arbitrary units/ . . .
. . . . . . . . pg/mm/unit vu/in
exha/ed/hr unit vu//in unit vu//in
1 2.7 2.63 92.8 48.5
2 2.9 2.34 1 18.9 32.4
3 1.8 5.19 93.9 165.9
4 3.5 2.33 44.6 76.4
S 0.9 1.84 19.1 29.0
6 4.9 7.16 150.9 277.6
7 3.5 4.81 61.9 109.5
8 3.2 3.02 1 10.6 60.8
9 4.3 1.93 40.9 41.1
10 1.8 3.71 32.5 57.8
11 3.0 1.46 33.6 71.1
12 3.5 3.09 136.9 124.2
13 2.0 2.44 121.2 78.5
14 4.3 2.15 112.8 40.5
15 4.7 5.41 52.4 86.8
16 4.4 1.59 76.2 65.8
17 6.8 3.49 164.7 114.9
18 2.4 3.01 - 83.8
19 2.3 0.63 35.0 5.8
20 3.1 2.27 88.7 95.6
obtained at multiple sites (fig. 1BJ, mean 128.6 ± 47.6 SD
optical density units/mg protein). However, there was an excel-
lent correlation between the CYP3A4 and villin protein levels as
determined by optical density (r = 0.958, p = 0.003 for same-
site biopsies; r = 0.948, p = 0.006 for separate site biopsies; see
fig. 1, A 1 and Bi). When the ratios of the optical densities of
CYP3A and villin immunoreactive proteins were calculated (see
fig. 1, A2 and B2), the interbiopsy variation was significantly
reduced (mean 1 .06 ± 0.04 SD, same-site biopsies, mean 0.468
± 0.065 SD for separate site biopsies). These observations suggest
that interbiopsy variation in enterocyte content does exist but
that this could be controlled for by expressing CYP3A protein
concentration relative to villin protein concentration. In addi-
tion, it seems that, with villin correction, the site of the biopsy
does not appear to be an important variable, at least within the
second portion of the duodenum.
We were unable to repeat the above study looking at CYP3A
and villin mRNAs, because the amount of RNA obtained from
a single biopsy was insufficient for hybridization analysis. How-
ever, because the regulation of villin is believed to be at the
transcriptional level or by RNA stabilization (34), it seems rea-
sonable to assume that villin mRNA could serve as an appropri-
ate control for our RNA studies.
Expression of CYP3A4 mRNA in Human Intestine. Intestinal
RNA obtained from each patient was analyzed on RNA blots.
The RNA from patient 18 had degraded asjudged by the absence
of clear ribosomal bands on the ethidium-stained agarose gels
and did not detectably hybridize with villin cDNA (fig. 2). We
were therefore unable to normalize the CYP3A4 mRNA expres-
sion to villin, and this patient was omitted from the RNA
analysis. As shown in fig. 2, the CYP3A4 cDNA hybridized to
two distinct RNA species of 2.2 and 3.0 kb characteristic for the
CYP3A4 gene (6). Because prior studies have shown that the
ratio of the intensity of the two bands is constant (6), we
quantitated only the more prominent 2.2 kb band by computer-
aided densitometry. The blot was then stripped and rehybridized
with a villin cDNA probe under stringent conditions (fig. 2).
Two RNA species were identified (2.8 and 3.6 kb), which corre-
spond to the two known villin mRNAs (35). As the two bands
are always equal in intensity (35), the lower band was chosen for
quantitation by computer densitometry.
There was a >7-fold variability in CYP3A4 mRNA concentra-
tion in the biopsies. This variability was not due to differences
in biopsy content of intact enterocytes, because there was an 8-
fold variability in CYP3A4 mRNA when corrected for villin
mRNA expression (CYP3A4 mRNA/villin mRNA; see table 2).
Mean levels of CYP3A4 mRNA were higher in women than in
men in both absolute terms (446 vs. 333 optical density units)
and when corrected for villin mRNA (99.2 vs. 69.5 optical
density units). However, these differences did not achieve statis-
tical significance (p = 0.29 and p = 0. 15, respectively). When
the ERMBT results were compared with the biopsy content of
CYP3A4 mRNA (uncorrected), there was a positive trend toward
a correlation that was not significant (r = 0.27, p = 0.26).
However, when the ERMBT results were compared with the
CYP3A4 mRNA corrected for villin mRNA, a modest, but
significant, positive correlation was observed (r = 0.49, p =
0.033; fig. 3).
Expression of CYP3A4 Protein in Human Intestine. The con-
centrations of CYP3A4 and villin immunoreactive protein were
determined in the 59 fraction prepared from the biopsies of each
patient using a quantitative immunoblot technique (described in
Materials and Methods). There was an 1 1-fold variation in the
biopsy concentration of either absolute CYP3A4 protein (130.4
± 69.3 SD fmol/tg protein) or the villin adjusted CYP3A4
protein (3.03 ± 1.57 SD fmol/ug protein/villin optical density
units; see table 2). Thus, the interpatient variation in intestinal
CYP3A4 protein content greatly exceeded the relatively small
degree of intrapatient variability we observed when multiple
biopsies were obtained from the same patient (see fig. 1). Women
were found to have significantly higher biopsy concentrations of
CYP3A4 protein than did men (165 fmol/mg protein vs. 102
fmol/mg protein, p = 0.039) and also had higher CYP3A4 to
villin ratios than did the men (3.84 fmol/unit villin vs. 2.36
fmol/unit villin, p = 0.032). There was no correlation between
the ERMBT result and biopsy concentration ofCYP3A4 protein
corrected for villin (r = 0.273, p = 0.24). There was also no
significant correlation between the CYP3A4 to villin protein
ratios and CYP3A4 to villin mRNA ratios (r = 0.367, p = 0.12).
Likewise, there was no significant correlation between biopsy
concentrations of CYP3A4 mRNA and CYP3A4 protein when
neither were corrected for villin expression (r = 0.241, p = 0.31).
Expression of CYP3AS Protein in Human Intestine. CYP3A5
has been shown to migrate slightly more slowly than CYP3A4
on SDS-polyacrylamide gel electrophoresis. The presence of both
CYP3A4 and CYP3A5 protein in liver microsomes therefore
produces a “doublet” on an immunoblot (7, 8). We did not
observe doublets in any of the intestinal samples, and the abun-
dance of CYP3A4 protein prevented attempts to visualize
CYP3A5 by prolonging the exposure of the immunoblots. To
provide a more sensitive means of detecting CYP3A5 protein,
duplicate immunoblots were probed with an antibody that has
been shown to recognize selectively CYP3A5 and not any of the
other CYP3A proteins (9). Protein from five of the patients
(patients 1, 6, 7, 14, and 17) readily reacted with the antibody
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FIG. I . Comparison ofimmunoreactive CYP3A4 and villin protein in single duodenal biopsies.
In the first patient (A), six biopsies were obtained within mm of each other, and in the second patient (B), six biopsies were obtained at least 1
cm apart. CYP3A4 and villin protein content were determined by immunoblot analysis of whole homogenate prepared from each biopsy. Biopsy
concentrations of CYP3A4 and villin protein were found to vary over 2-fold; however, there was an excellent intrapatient correlation between the
amount of CYP3A4 and villin protein in biopsies obtained at either the same site (Al; r = 0.96, p = 0.003) or different sites (B!; r = 0.95, p =
0.006). When CYP3A4 protein was expressed as a ratio with villin protein, the interbiopsy variation was significantly reduced with either same-site
(A2, mean I .06 ± 0.04 SD) or different site biopsies (B2, mean 0.468 ± 0.065 SD).
Ethidium Stain
28 S
185
CYP3A4 
Patient Number
- (.4 ,e’  N ooO 2    i:  
V.’. 3.6kbI ifl 2 8
FIG. 2. RNA blot anal.vsis ofintestinal RNA for expression ofCYP3A4 and villin.
Intestinal RNA (30 g) from the 20 patients was subjected to electrophoresis in a formaldehyde containing agarose gel and transferred to
nitrocellulose. Densitometry of the ethidium-stained gel revealed significant degradation of the RNA only from patient 18. The blot was sequentially
hybridized with a CYP3A4 cDNA and a villin cDNA as described in Materials and Methods. The resulting bands are shown above with approximate
molecular weights indicated at the left.
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FIG. 3. Correlation between the ERMBT result and enleroci’le content of
CYP3.44 mRN,4.
Enterocyte CYP3A4 mRNA expression was estimated in the 19 pa-
tients with evaluable RNA data using the ratio of CYP3A4 mRNA to
villin mRNA content as determined by the integrated optical densities
of the appropriate bands on the RNA blot shown in fig. 2. A significant
correlation was observed between the ERMBT result and enterocyte
CYP3A4 (r = 0.49, p = 0.03). #{149},male; 0, female.
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Enterocyte CVP3A4 mRNA Content
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FIG. 4. Comparison ofrepresentative immunoblot analyses of small
bowel proteinfor expression ofCYP3A4. CYP3A5, and villin.
Triplicate immunoblots were developed with either an antibody that
preferentially identifies CYP3A4, an antibody that specifically identifies
CYP3A5, or an antibody that specifically identifies villin (see Materials
and Methods).
producing distinct bands (see fig. 4 for representative samples).
This reactive protein comigrated with purified CYP3A5 on poly-
acrylamide gels (not shown). With prolonged exposure of the
film, we were able to detect CYP3A5 protein in all but six
patients (patients 5, 6, 8, 1 2, 1 3, and 19; data not shown). The
immunoreactive protein could not be quantitated, because of
the absence of an appropriate standard on the blots. Nonetheless,
there was clearly marked heterogeneity in expression of this
protein, and there was no correlation between the biopsy content
CYP3A5 and CYP3A4 immunoreactive protein (fig. 4 and data
not shown).
CYP3A Catalytic Activity Analysis. The biopsy S9 protein
0 fractions were analyzed for their ability to metabolize midazolam
to its 1 ‘- and 4-OH metabolites. These reactions have been shown
to be rapidly catalyzed by CYP3A4 in liver microsomes (36).
There was a >6-fold variability in the 1 ‘-hydroxylation and the
4-hydroxylation ofthis substrate after correction for villin protein
concentration (see table 2). The ratio of the 1 ‘-OH to 4-OH
metabolite formation rates was 5.26 ± 1 .59 SD, but there was a
nearly perfect correlation between these two measurements (r =
0.98, p < 0.000 1 ). CYP3A5 has also been reported to hydroxylate
midazolam (37), but the presence of detectable CYP3A5 in 14
patients did not seem to influence either the total production of
the hydroxylated metabolites, or the ratio of the rates of produc-
tion of the two metabolites measured (data not shown). Equiva-
lent results were obtained using either the 1 ‘-OH or the 4-OH
metabolite formation rate in the following comparisons; there-
fore, only the correlations for the 1 ‘-OH metabolite formation
200 rate are given.
Women had higher midazolam hydroxylation rates than men
in terms of both absolute (44.7 vs. 29.0 pg 1 ‘-OH/mm/mg
protein) or villin-corrected 1 ‘-OH metabolite formation (101.1
vs. 68.7 pg 1 ‘-OH/mm/arbitrary villin unit), although this was
not significant (p = 0.20 and p = 0.23, respectively). There was
no significant correlation between the rates of midazolam me-
tabolism and the ERMBT results, whether the catalytic activities
were expressed/mg intestinal protein (r = 0.40, p = 0.08) or
corrected for biopsy content of villin (r = 0.33, p = 0. 1 5; fig. 5).
There was, however, an excellent correlation between the enter-
ocyte CYP3A4 protein content and the midazolam hydroxyl-
ation activity (r = 0.856, p < 0.0001 ; fig. 6). This correlation was
highly significant even when the patient with the highest
CYP3A4 protein and catalytic activity (patient 6) was excluded
(r = 0.725, p = 0.0005).
Discussion
There are well-established interpatient differences in the liver
content and catalytic activity of CYP3A4 that are believed to
Enterocyte Midazolam I ‘-Hydroxyiation
(pg / mm I arbitrary viiiin unit)
FIG. 5. Comparison ofthe ERMBT result and enterocyte catalytic
activity (midazolam 1 ‘-hydroxylation).
Midazolam 1 ‘-hydroxylation activity was determined in the S9 frac-
tions prepared from intestinal biopsies. To correct for interbiopsy varia-
tion in enterocyte number and variation in protein degradation, the
catalytic rates were divided by the biopsy content of villin protein
(expressed in arbitrary optical density units measured on immunoblots).
The correlation observed was not significant (r = 0.33, p = 0. 15). #{149},
male; 0, female.
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FIG. 6. Correlation between the concentration ofCYP3A4 protein and
mida:olam 1 ‘-hydroxylase activity in intestinal biopsies.
CYP3A4 protein and midazolam 1‘-hydroxylase activity assays were
performed on aliquots of the same S9 protein fractions; therefore, no
correction by villin was necessary. The observed correlation is highly
significant (r = 0.86, p < 0.0001). When the patient with the highest
CYP3A4 protein and catalytic activity was excluded, the correlation
remained highly significant (r = 0.73, p = 0.0005). #{149},male; 0, female.
account, in part, for interpatient differences in the dosing require-
ments of some drugs. In this study, our first objective was to
determine whether interindividual heterogeneity in the expres-
sion of CYP3A4 also exists in the small bowel. We found that
there was indeed extensive variability in the expression of this
enzyme. There was a >8-fold variability in CYP3A4 mRNA
content, a >1 I-fold variation in CYP3A4 protein content, and a
>6-fold variation in catalytic activity characteristic of CYP3A
enzymes (1 ‘-OH midazolam formation). This heterogeneity was
unchanged when the results were expressed relative to the expres-
sion of villin, an enterocyte-specific protein (see table 2). Our
data, therefore, indicate that there is significant heterogeneity in
intestinal expression of CYP3A4 and that this heterogeneity is
comparable with that found in liver.
We also detected CYP3A5 protein in the intestinal samples of
70% (14 of 20) of the patients studied. This enzyme is present in
roughly 25% of adult livers and, although we had no way to
determine which of our patients had hepatic expression of
CYP3A5, our results suggest that CYP3A5 may be more corn-
monly expressed in the intestine than in the liver. The intestinal
concentration of CYP3A5 protein, which seemed to vary greatly
among patients, was not at all correlated with that of CYP3A4
protein (illustrated in fig. 4). This suggests that, in the intestine,
as in the liver, these two enzymes are independently regulated.
It is likely that CYP3A5 is expressed at lowerlevels than CYP3A4
in the intestine, because we could only detect the presence of
CYP3A5 using an antibody specific for this protein. In addition,
the presence of detectable CYP3A5 did not seem to influence
the total midazolam metabolism measured (data not shown).
Furthermore, we have previously been unable to detect CYP3A5
rnRNA on RNA blots of human small intestinal RNA using a
CYP3A5-specific oligonucleotide probe (16). We conclude that
when compared with CYP3A4, it seems to be a relatively minor
enzyme.
The second major aim of our study was to determine whether
the ERMBT result predicted intestinal CYP3A4 catalytic activ-
ity. It did not (fig. 5). It is unlikely that the lack of a correlation
between the ERMBT and intestinal midazolarn metabolism was
due to variable inactivation of the enzyme during processing of
the tissue, because there was an excellent correlation between
the catalytic activity and the biopsy content ofCYP3A4 protein.
In addition, when CYP3A4 protein and catalytic activity meas-
urements were corrected for protein degradation and enterocyte
content (by villin content), no correlation with the ERMBT
results was observed. The discrepancy between the ERMBT
result and intestinal expression of CYP3A enzymes is illustrated
by patient 19, who had an ERMBT result of2.33%. This result
is normal for a man (10, 19) and comparable with the ERMBT
values of patient 1 8 (2.35%) and patient 20 (3. 1 1 %). However,
whereas both patients 18 and 20 had relatively high levels of
CYP3A4 protein, patient 19 had almost no detectable CYP3A4
protein (fig. 4 and table 2), no detectable CYP3A5 (fig. 4), and
the lowest midazolam 1 ‘-hydroxylation rate ofall ofthe patients
studied (table 2). This could not be explained on the basis of
protein degradation in patient 19’s biopsies, because villin pro-
tein was present at roughly the same level as was observed in the
intestinal biopsies from the other patients (fig. 4).
Because our study was performed in patients and not in healthy
volunteers, it is possible that some of the heterogeneity in
CYP3A4 expression we observed was due to the effects of medi-
cations or disease. Five patients were receiving known substrates
for CYP3A enzymes [patients 3 and 8 (estrogen), patient 9
(nifedipine), patient 12 (terfenadine), and patient 16 (triazolam);
see table 1 ]. However, removal of these patients from the data
base did not alter any conclusions (not shown). In addition, none
of the patients were receiving any known inducers or noncom-
petitive inhibitors of CYP3A enzymes (table 1), and all biopsies
were obtained from normal-appearing tissue.
Because liver CYP3A4 seems to be measured by the ERMBT,
our observations suggest that regulation of the CYP3A4 gene in
the liver and the intestine is not closely linked. Discordant
regulation of liver and intestinal CYP3A proteins has also been
reported in rats treated with certain diets (38). Our data may
provide some insight into this issue. In a previous study, we
showed that CYP3A4 mRNA and protein were induced in the
intestine of volunteers taking rifampin (16). This indicates that
pretranslational control of CYP3A4 gene expression can occur
in the intestine as has been shown in the liver (20). Although it
is speculative, our finding that the ERMBT result correlated with
the intestinal concentration of CYP3A4 mRNA (fig. 3) may
indicate a degree of coordinate regulation between the liver and
the intestine at the pretranslational level. We did not, however,
find a correlation between the concentrations ofCYP3A4 mRNA
and CYP3A4 protein or catalytic activity in the biopsies. This
may suggest that posttranslational factors are also involved in
the regulation of CYP3A4 in the intestine. It is unlikely that
incorporation of heme into the enzyme protein is an important
step in the regulation of intestinal CYP3A4 catalytic activity,
because there was an excellent correlation between intestinal
protein and catalytic activity measurements in this study (fig. 6).
It seems reasonable to assume from our studies that heteroge-
neity in intestinal expression of CYP3A4 may be responsible for
part of the variable first-pass metabolism of orally administered
CYP3A4 substrates. This idea is supported by a recent study in
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to administer the metabolic probe orally.
which the pharmacokinetics of oral and intravenously adminis-
tered cyclosporin A were determined in normal volunteers before
and after treatment with rifampin (39). Rifampin was found to
reduce dramatically the oral clearance of cyclosporin A while
having a relatively small effect on the systemic clearance of the
drug. The authors concluded that this drug interaction was
primarily due to induction by rifampin of intestinal metabolism
of cyclosporin A. We have previously shown that treatment of
patients with rifampin results in a 4- to 8-fold induction in
CYP3A4 mRNA expression and in CYP3A4 catalytic activity in
the enterocyte (16). Therefore, the 8- to 1 1-fold variation in
CYP3A4 expression we observed in these 20 patients in the
absence of known inducers should be of sufficient magnitude to
influence significantly the oral bioavailability of drugs that are
CYP3A4 substrates. Differences in intestinal CYP3A activity
may therefore in part account for the variation in cyclosporin A
kinetics that was not accounted for by differences in the ERMBT
result in our previous studies (1 3, 14). In particular, this may
account for the fact that the ERMBT results did not at all
correlate with the peak cyclosporin A blood levels (14), a param-
eter that should largely reflect first-pass metabolism. The tech-
niques developed for the current study, which allow accurate
estimation of enterocyte CYP3A4 activity from a single pinch
biopsy of small bowel mucosa, will make it possible to test these
hypotheses directly in future studies.
Intestinal CYP3A enzymes have recently been shown to con-
vert dietary aflatoxin B to reactive metabolites that form afla-
toxin B1 macromolecular adducts within enterocytes (40). These
adducts should pass harmlessly in stool as the enterocytes are
shed. In perhaps a similar manner, intestinal CYP3A enzymes
have also been shown to bioactivate heterocyclic amines to
mutagenic metabolites (41). In addition, CYP3A4 has been
shown to convert aflatoxin B1 to Q, which may represent a
detoxification pathway (42). For these reasons, intestinal CYP3A
enzymes may provide a protective barrier to dietary xenobiotics.
Interindividual variation in intestinal content of CYP3A en-
zymes may therefore represent a previously unrecognized risk
factor for certain environmental diseases.
As a final point, it has been reported that liver microsomes
obtained from women have a higher specific activity of CYP3A
enzymes than do liver microsomes obtained from men (43).
Gender differences in the expression of CYP3A have also been
demonstrated in rats in both the liver and the intestine (44, 45).
Each parameter of intestinal CYP3A4 expression that we exam-
med (1 ‘-OH metabolite formation, 4-OH metabolite formation,
CYP3A4 protein, and CYP3A4 mRNA) was higher in women
than in men. Although our sample size was small, our observa-
tions suggest that there may be gender differences in intestinal
CYP3A4 expression in humans.
In summary, we have shown that there is a marked interpatient
heterogeneity in enterocyte expression ofCYP3A4 and CYP3A5.
It seems likely that this heterogeneity accounts, at least in part,
for interpatient differences in the kinetics of orally administered
CYP3A substrates. In addition, our results suggest that metabolic
probe-based assays that exclusively measure liver CYP3A4, such
as the ERMBT, are unlikely to predict accurately the first-pass
metabolism of orally administered substrates. In the future, if
the aim is to develop a test that will be useful in orally dosing
medications that are CYP3A4 substrates, it would seem logical
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